Down-regulation of BAX Gene During Carcinogenesis and Acquisition of Resistance to 5-FU in Colorectal Cancer

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2013 Oct 15

PMID 24122668

Citations 20

Authors

Mehdi Manoochehri

Ashraf Karbasi

Mojgan Bandehpour

Bahram Kazemi

Affiliations

Soon will be listed here.

Abstract

Carcinogenesis and resistance to chemotherapy could be as results of expression variations in apoptosis regulating genes. Changes in the expression of apoptosis interfering genes may contribute to colorectal carcinogenesis and resistance to 5-Flourouracil (5-FU) during treatment schedule period. The present study aimed to evaluate the expression of pro-apoptotic and anti-apoptotic genes in colorectal cancer tumor tissues, normal adjacent tissues, and tumor colorectal cancer cell line during acquiring resistance to 5-FU in HT-29 based on Bolus treatment protocol. The normal and tumor tissues were obtained from hospital after surgery and total RNA was extracted for expression analysis. The HT-29 colorectal cancer cell line was cultured and exposed with 5-FU in three stages based on Bolus protocol. The MTT assay and Real Time PCR were carried out to determine the sensitivity to the drug and expression of desired genes, respectively. The obtained data showed that Proapoptotic genes, BAX and BID, were down-regulated in resistant derivate cells compared to wild type HT-29 cells. On the other hand Antiapoptotic genes, CIAP1 and XIAP, showed upregulation in resistant cells compared to wild type ones. Furthermore, BAX and FAS genes showed down-regulation in tumor samples in comparison to normal adjacent tissues. In conclusion, the results of our study suggest that BAX down-regulation could contribute as an important factor during both colorectal carcinogenesis and cell resistance to 5-FU.

Citing Articles

Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges.

Zhang Z, Hou L, Liu D, Luan S, Huang M, Zhao L Acta Pharm Sin B. 2024; 14(6):2378-2401.

PMID: 38828138 PMC: 11143528. DOI: 10.1016/j.apsb.2024.02.010.

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y Signal Transduct Target Ther. 2024; 9(1):132.

PMID: 38763973 PMC: 11102923. DOI: 10.1038/s41392-024-01823-2.

A novel immunogenic cell death-related gene risk signature can identify biomarkers of gliomas and predict the immunotherapeutic response.

Tang X, Wang K, Yang J, Wang Y, Yan Z Am J Cancer Res. 2024; 14(1):324-343.

PMID: 38323285 PMC: 10839322.

Innovative microwave-assisted biosynthesis of copper oxide nanoparticles loaded with platinum(ii) based complex for halting colon cancer: cellular, molecular, and computational investigations.

Sedky N, Fawzy I, Hassan A, Mahdy N, Attia R, Shamma S RSC Adv. 2024; 14(6):4005-4024.

PMID: 38288146 PMC: 10823359. DOI: 10.1039/d3ra08779d.

Kynureninase knockdown inhibits cisplatin resistance in vivo and in vitro and impacts the prognosis of cervical adenocarcinoma.

Zhang J, Wang Y, Zhong M, Liang M Cell Div. 2023; 18(1):15.

PMID: 37742026 PMC: 10518096. DOI: 10.1186/s13008-023-00098-3.

References

Sax J, Fei P, Murphy M, Bernhard E, Korsmeyer S, El-Deiry W . BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 2002; 4(11):842-9. DOI: 10.1038/ncb866. View

Humeniuk R, Menon L, Mishra P, Gorlick R, Sowers R, Rode W . Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009; 8(5):1037-44. DOI: 10.1158/1535-7163.MCT-08-0716. View

Pourhoseingholi M . Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol. 2012; 4(4):68-70. PMC: 3334381. DOI: 10.4251/wjgo.v4.i4.68. View

Park S, Bae J, Nam B, Yoo K . Aetiology of cancer in Asia. Asian Pac J Cancer Prev. 2008; 9(3):371-80. View

Samuel S, Fan F, Dang L, Xia L, Gaur P, Ellis L . Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene. 2010; 30(10):1205-12. PMC: 3224802. DOI: 10.1038/onc.2010.496. View

Berger F, Berger S . Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years?. Cancer Biol Ther. 2006; 5(9):1238-41. DOI: 10.4161/cbt.5.9.3414. View

Buroker T, Oconnell M, Wieand H, Krook J, Gerstner J, Mailliard J . Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 1994; 12(1):14-20. DOI: 10.1200/JCO.1994.12.1.14. View

Petak I, Danam R, Tillman D, Vernes R, HOWELL S, Berczi L . Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ. 2003; 10(2):211-7. DOI: 10.1038/sj.cdd.4401132. View

Zhang N, Yin Y, Xu S, Chen W . 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008; 13(8):1551-69. PMC: 6244944. DOI: 10.3390/molecules13081551. View

10.

Igney F, Krammer P . Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002; 2(4):277-88. DOI: 10.1038/nrc776. View

11.

Jansson A, Sun X . Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol. 2002; 20(3):811-6. DOI: 10.1200/JCO.2002.20.3.811. View

12.

Guillen-Ahlers H, Suckow M, Castellino F, Ploplis V . Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS One. 2010; 5(2):e9070. PMC: 2816700. DOI: 10.1371/journal.pone.0009070. View

13.

Katkoori V, Suarez-Cuervo C, Shanmugam C, Jhala N, Callens T, Messiaen L . Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2012; 1(2):76-89. PMC: 3397579. DOI: 10.3978/j.issn.2078-6891.2010.019. View

14.

Elmore S . Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4):495-516. PMC: 2117903. DOI: 10.1080/01926230701320337. View

15.

Watson A . Apoptosis and colorectal cancer. Gut. 2004; 53(11):1701-9. PMC: 1774275. DOI: 10.1136/gut.2004.052704. View

16.

Luo X, Budihardjo I, Zou H, Slaughter C, Wang X . Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998; 94(4):481-90. DOI: 10.1016/s0092-8674(00)81589-5. View

17.

Shaib W, Lee V, Saif M . Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. In Vivo. 2009; 23(5):821-6. View

18.

Arnold C, Goel A, Boland C . Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003; 106(1):66-73. DOI: 10.1002/ijc.11176. View

19.

Piedbois P, Rougier P, Buyse M, Pignon J, Ryan L, Hansen R . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16(1):301-8. DOI: 10.1200/JCO.1998.16.1.301. View

20.

Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M . Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci. 2009; 100(5):903-13. PMC: 11159709. DOI: 10.1111/j.1349-7006.2009.01112.x. View